Biotechnology Innovation Organization

Last updated
Biotechnology Innovation Organization
NicknameBIO
Purpose Lobbying
Key people
 John Crowley (CEO)
Website https://www.bio.org/
Formerly called
Biotechnology Industry Organization

The Biotechnology Innovation Organization (BIO) is the largest advocacy association in the world representing the biotechnology industry. [1] [2] [3] It was founded in 1993 as the Biotechnology Industry Organization from a merger of the Industrial Biotechnology Association (IBA) and the Association of Biotechnology Companies (ABC), [4] and changed its name to the Biotechnology Innovation Organization on January 4, 2016. [5] [6] Biotechnology Innovation Organization serves more than 1,100 biotechnology firms, research schools, state biotechnology centers and related associations in the United States and in more than 30 other countries. [7]

Contents

Activities

Annual conference

BIO holds its annual international conference each year in the United States. This conference provides networking, business development and partnering activities that are essential to the biotechnology industry, in which developing products take considerable time and resources and regulatory risks are high. [8] In 2021, BIO shifted its in-person meetings to virtual, due to restrictions and difficulties arising from the COVID-19 pandemic. [9]

Lobbying

In 2018, BIO spent $9.87 million on lobbying the government of the United States. [10] Past issues that BIO has lobbied on included the amending the Internal Revenue Code to provide an exception from the passive loss rules for investments in high-technology research small business pass-through entities, to include vaccines against seasonal influenza within the definition of taxable vaccines, and to extend, expand, and improve the qualifying therapeutic discovery project program that first became law in 2010. [11] [12]

Examples of its public lobbying efforts, include support for development of biofuels such as those produced from algae, [13] genetically modified crops, [14] strong intellectual property rights, [15] and for a more efficient and predictable regulatory process for new food and drug products. [16]

Alliances

In June 2013 BIO partnered with the Coalition of Small Business Innovators to lobby the U.S. government to modernize the U.S. tax code "to recognize and promote small business innovation as fundamental to the long-term growth of the U.S. economy". [17] [18]

It is a member of The Alliance to Feed the Future, an umbrella network, the mission of which is to "raise awareness and improve understanding of the benefits & necessity of modern food production and technology in order to meet global demand". [19] [20]

Industry initiatives

The "Right Mix Matters" campaign launched in 2019 targets diversity within biopharmaceutical company leadership, including ongoing assessment of diversity measures (gender, race, ethnicity, sexual orientation) and the provision of online tools aimed at assisting companies to achieve target diversity goals. [6]

Organization

Members

John Crowley was announced as BIO's CEO in 2023. John F. Crowley.jpg
John Crowley was announced as BIO's CEO in 2023.

BIOs members include companies that make pharmaceutical drugs, biofuels, industrial enzymes, and genetically modified crops, as well as healthcare facilities that participate in clinical trials and biopharmaceutical research. [21] As of 2016, it represents 1,100 biotech companies in all 50 U.S. states, which employ 1.61 million Americans and support an additional 3.4 million jobs. [17]

Leadership

BIO was founded in 1993 in Washington, D.C., and Carl B. Feldbaum was the president from BIO's founding until he retired in 2004. [22] He was succeeded by James C. Greenwood who held the offices of president and CEO from 2005 to 2020.

The association has a 120-member board, consisting of a diverse mix of company executives based upon size, geography, and pharmaceutical focus. The board's executive committee consists of 21 members, purposefully designed to ensure a representative voice for the smaller companies among BIO's membership. [23]

After Congressman Greenwood's 15 years of service, the BIO board announced scientist and former FDA regulator Michelle McMurry-Heath would become president and CEO as of 1 June 2020. [24] McMurry-Heath was placed on leave sometime prior to October 6, 2022, reportedly as a result of disagreements with a small but influential group of board members who wanted the organization to use its clout to advance social issues not directly connected to its industry interests. [23] Additionally, questions had been raised by some board members about her performance and management style. [23] [25] Heath resigned effective October 11, 2022, with GlycoMimetics co-founder and former CEO Rachel King tapped to serve as interim CEO of the organization. [25] In 2023, John Crowley, Executive Chairman of Amicus Therapeutics, was announced as BIO's next CEO. Crowley has a background in rare diseases and is credited with working on a drug to save his children's and all individuals with Pompe disease's hearts. His work was the subject of the movie Extraordinary Measures which starred Brendan Fraser and Harrison Ford. [26]

Biotechnology Heritage Award

The Biotechnology Heritage Award, presented annually at the Biotechnology Innovation Organization (BIO) Annual International Convention by the Biotechnology Innovation Organization (BIO) and the Science History Institute (formerly the Chemical Heritage Foundation), recognizes individuals who have made significant contributions to the development of biotechnology through discovery, innovation, and public understanding. [27]

Related Research Articles

The pharmaceutical industry in India was valued at an estimated US$42 billion in 2021 and is estimated to reach $130 billion by 2030. India is the world's largest provider of generic medicines by volume, with a 20% share of total global pharmaceutical exports. It is also the largest vaccine supplier in the world by volume, accounting for more than 60% of all vaccines manufactured in the world. Indian pharmaceutical products are exported to various regulated markets including the US, UK, European Union and Canada.

Arthur D. Levinson is an American businessman and is the chairman of Apple Inc. (2011–present) and chief executive officer (CEO) of Calico. He is the former CEO (1995–2009) and chairman (1999–2014) of Genentech.

John Mendlein is a biotech executive who has held leadership positions in biotech companies in Boston, San Diego and Toronto.

<span class="mw-page-title-main">Cristina Garmendia</span> Spanish biologist and businesswoman (born 1962)

Cristina Garmendia y Mendizábal is a Spanish biologist and businesswoman. With no previous political career, she was appointed as Minister of Science and Innovation in April 2008 by the President of the Government of Spain, Jose Luis Rodriguez Zapatero.

China has seen double-digit growth in its biotechnology industry and has gone from being one of the slowest to one of the fastest nations in the adoption of new biotechnologies. The biotech sector is seen in China and internationally as a core area of national scientific and economic development. The main national biotech body in the country is the China National Center for Biotechnology Development. The CNCBD is an organization established on November 3, 1983, under the Ministry of Science and Technology with the approval of the State Council. CNCBD is the sole national center to coordinate and implement the national S&T program in Biotechnology and Health.

Michelle Dipp is an American scientist, businesswoman, and investor. She is the co-founder and a managing partner at Biospring Partners and serves on the board of Abzena and Kiniciti.

Life Sciences Foundation (LSF) was a San Francisco-based nonprofit organization that was established in 2011 to collect, preserve, interpret, and promote the history of biotechnology. LSF conducted historical research, maintained archives and published historically relevant materials and information.

<span class="mw-page-title-main">Jeremy Levin</span> American businessman

Jeremy Levin is a South African-born businessman, medical doctor and research scientist. In 2018, Levin was named as one of the most influential figures in the biopharmaceutical industry.

Arie S. Belldegrun, FACS, is an Israeli-American urologic oncologist, billionaire businessman and investor.

IQnovate is an Australian life sciences organization that provides intellectual property asset management services and scientific advice to the biopharmaceutical industry. The company is best known for providing services to government organizations and some of the world's largest biopharmaceutical organizations. IQnovate is listed on the National Stock Exchange of Australia under the ticker symbol IQN and on the OTC in New York under the symbol IQNDY.

<span class="mw-page-title-main">Geoffrey von Maltzahn</span> American inventor

Geoffrey von Maltzahn is an American biological engineer and businessman in the biotechnology and life sciences industry who has founded a number of companies including Indigo Agriculture, Sana Biotechnology, Kaleido Biosciences, Seres Therapeutics, Axcella Health, Generate Biomedicines and Tessera Therapeutics. He has over 200 bioengineering and biotechnology patents and applications.

<span class="mw-page-title-main">Nancy T. Chang</span> Biochemist

Nancy Tang Chang, née Tang Nanshan, is a biochemist who cofounded Tanox in 1986 to address medical needs in the areas of allergy, asthma, inflammation and diseases affecting the human immune system. Tanox took an innovative approach in developing an asthma drug that focused on the allergy-related basis of asthma, Xolair. In June 2003, the U.S. Food and Drug Administration (FDA) approved Xolair, the first biotech product cleared for treating those with asthma related to allergies. Tanox was also active in the development of TNX-355, an antibody for the treatment of HIV/AIDS. In 2007, Tanox was sold to Genentech for $919 million. Dr. Chang grew Tanox from an idea to a substantial publicly traded company, doing innovative science. Following her success with Tanox, she has become an angel investor in health-care entrepreneurships and performs philanthropic work in community health-education projects.

Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.

<span class="mw-page-title-main">Henri Termeer</span>

Henri A. Termeer was a Dutch biotechnology executive and entrepreneur who is considered a pioneer in corporate strategy in the biotechnology industry for his tenure as CEO at Genzyme. Termeer created a business model adopted by many others in the biotech industry by garnering steep prices— mainly from insurers and government payers— for therapies for rare genetic disorders known as orphan diseases that mainly affect children. Genzyme uses biological processes to manufacture drugs that are not easily copied by generic-drug makers. The drugs are also protected by orphan drug acts in various countries which provides extensive protection from competition and ensures coverage by publicly funded insurers. As CEO of Genzyme from 1981 to 2011, he developed corporate strategies for growth including optimizing institutional embeddedness nurturing vast networks of influential groups and clusters: doctors, private equity, patient-groups, insurance, healthcare umbrella organizations, state and local government, and alumni. Termeer was "connected to 311 board members in 17 different organizations across 20 different industries" He has the legacy of being the "longest-serving CEO in the biotechnology industry.

Neurobiological Technologies, Inc. ("NTI") was a biotechnology company that was founded in 1987 by Enoch Callaway and John B. Stuppin to in-license and develop drugs primarily to treat neurological conditions; the company was dissolved in 2009 after the failure of its drug candidate ancrod in a Phase III trial for ischemic stroke.

<span class="mw-page-title-main">William Rastetter</span> American scientist, entrepreneur and venture capitalist

William H.Rastetter, a scientist, entrepreneur and venture capitalist, is the chair of Neurocrine Biosciences, of Fate Therapeutics, and of Daré Bioscience, Inc. in San Diego, California. He is a founding board member and investor in GRAIL, Inc. in Menlo Park, California, and served for a period as the company's interim CEO (2017) and chair (2017-2018). Rastetter is also a director of Regulus Therapeutics and Entos, Inc.. He was a partner in the venture firm Venrock (2006-2013), and a trustee at Caltech (2015-2018). He has served as a director (1998-2016) and as chair of Illumina (2005-2016). He advised SVB Leerink (2014-2019) and currently advises Illumina Ventures.

<span class="mw-page-title-main">Michelle McMurry-Heath</span> American Immunologist

Michelle McMurry-Heath is a medical doctor, immunologist, and from June 2020 until October 2022 served as chief executive officer for the Biotechnology Innovation Organization (BIO).

<span class="mw-page-title-main">Albert Bourla</span> CEO of Pfizer

Albert Bourla is an American-Greek veterinarian and the chairman and chief executive officer of Pfizer, an American pharmaceutical company. He joined the company in 1993 and has held several executive roles across Pfizer's divisions. Prior to becoming chief executive officer, Bourla was chief operating officer.

John Maraganore is an American scientist, entrepreneur, and life sciences industry leader.

BIOTECanada, or the Industrial Biotechnology Association of Canada, is a Canadian biotechnology industry association based in Ottawa, Ontario. It is an industry-funded membership organization composed of over 250 national and international pharmaceutical and gene therapy companies, medical device manufacturers, agricultural science businesses, law firms, academic institutions, research and development networks, advertising agencies, insurance companies and financial services firms.

References

  1. ↑ Anna Edney, "Biosciences Defy U.S. Jobs Slump as Research Labs Hire", Bloomberg News, June 19, 2012.
  2. ↑ European Biotechnology Network. "List of European and International Biotech Industry Associations" Archived 2019-01-29 at the Wayback Machine
  3. ↑ "GEN's 30th Anniversary: Biotech Trade Associations", Genetic Engineering News, June 15, 2011.
  4. ↑ "BIO: Making History". Biotechnology Innovation Organization. Retrieved 24 February 2023.
  5. ↑ "Biotechnology Innovation Organization changes name to Biotechnology Innovation Organization" (Press release). BusinessWire. 4 January 2016. Retrieved 4 July 2019.
  6. 1 2 Wright, Rob (1 July 2019). "Increasing Diversity Among Leadership And Boards". Life Science Leader. VertMarkets.
  7. ↑ "About BIO". diapharma. June 2017. Retrieved 22 May 2020.
  8. ↑ Robert Weisman, "Biopharmaceutical industry faces a shift in dynamics", Boston Globe, April 23, 2013.
  9. ↑ "BIO lays off staff to adapt to another year of virtual events". FierceBiotech. Retrieved 2021-01-25.
  10. ↑ OpenSecrets "Lobbying: Biotechnology Innovation Organization", Page Accessed January 2, 2020
  11. ↑ OpenSecrets "Bills lobbied", Page Accessed June 7, 2013
  12. ↑ Drew Armstrong, "Promising' Biotechnology Medicines May Earn $5 Million U.S. Tax Credit", Bloomberg News, May 21, 2010.
  13. ↑ Kambiz Foroohar for Bloomberg News. June 3, 2010. Exxon $600 Million Algae Investment Makes Khosla See Pipe Dream
  14. ↑ Elaine Watson, "It's not too late to change the conversation on GMOs: Interview with Cathy Enright, Executive VP for Food and Biotechnology, BIO", Food Navigator, May 20, 2013.
  15. ↑ Victoria Slind-Flor, "LG, DuPont, Bank of America, GM: Intellectual Property", Bloomberg News, December 3, 2012.
  16. ↑ Robert Weisman, "Federal drug review nettles biotech industry", Boston Globe, June 19, 2012.
  17. 1 2 "Biotechnology Innovation Organization Joins Coalition of Small Business Innovators" Archived 2014-11-04 at the Wayback Machine , BIO Press Release, June 4, 2013.
  18. ↑ "Coalition of Small Business Innovators Official Website". Archived from the original on 2017-09-30. Retrieved 2016-01-04.
  19. ↑ Alliance to Feed the Future Official Website Archived May 11, 2013, at the Wayback Machine
  20. ↑ PR Web. Monday, March 18, 2013 "Alliance to Feed the Future Congratulates Our Farmers, Supports Education for Future Generations on National Agriculture Day"
  21. ↑ "BIO profile at Biospace". Archived from the original on 2017-10-13. Retrieved 2016-01-04.
  22. ↑ "BIO President Carl Feldbaum to Retire at Year End" (Press release). Biotechnology Innovation Organization. 2 February 2004. Retrieved 15 July 2009.
  23. 1 2 3 Megan Wilson (October 28, 2022). "No win situation: Pharma CEO steps down after clashing with board members". Politico.
  24. ↑ "BIO Appoints a Physician-Scientist as New President and CEO". BusinessWire. May 14, 2020. Retrieved 19 May 2020.
  25. 1 2 Hopkins, Jared S (October 10, 2022). "BIO Chief Executive Michelle McMurry-Heath Exits After Clashes With Board". The Wall Street Journal . Retrieved 26 October 2022.
  26. ↑ Journal, Betsy McKay | Photographs by Clark Hodgin for The Wall Street (2023-12-05). "WSJ News Exclusive | He Designed Drugs to Save His Children. Now He's Working to Save Biotech, Too". WSJ. Retrieved 2024-01-04.
  27. ↑ "Biotechnology Heritage Award". Science History Institute . 31 May 2016. Retrieved 21 February 2018.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.